Craft
  • Home
  •  / Cabaletta Bio
Cabaletta Bio

Cabaletta Bio

Drugs in Development

4

Oct, 2019

Market Capitalization

$22.3 M

2022-09-19

Cabaletta Bio Summary

Company summary

Overview
Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. Its therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells.
Type
Public
Founded
2017
HQ
Philadelphia, PA, US | view all locations
Website
https://www.cabalettabio.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Steven Nichtberger

    Steven Nichtberger, President, Chief Executive Officer, and Co-Founder, Chairman

    • Catherine Bollard

      Catherine Bollard, Director

      • David J. Chang

        David J. Chang, Chief Medical Officer

        • Richard Henriques

          Richard Henriques, Director

          Operating MetricsView all

          Drugs in Development

          4

          Oct, 2019

          Discovery Stage Products

          2

          Oct, 2019

          Pre-Clinical Phase Products

          1

          Oct, 2019

          LocationsView all

          1 location detected

          • Philadelphia, PA HQ

            United States

            Cira Centre, 2929 Arch St #600

          Cabaletta Bio Financials

          Summary financials

          Footer menu